MARS Global · Embedded Biostatistics Author Services
0%of all medical paper retractions are caused by data and statistical issues — the single largest category, ahead of fraud. Retraction Watch Database · 50-year analysis, PMC 2024
MARS Global sits upstream of the single largest documented cause of retraction in your journals.
An embedded biostatistics review, built into your author journey, referred at the moment it matters most, with full Manuscript ID reconciliation and publisher revenue share.
Request a capabilities conversationExecutive Summary
The case in three paragraphs
Peer review has not solved the statistical-error problem in academic publishing. Independent studies spanning three decades put the prevalence of statistical errors or misreporting in published biomedical research at between 38% and 64%, depending on specialty. More consequentially, a 50-year analysis of the Retraction Watch Database confirms that data and statistical issues are the single largest documented cause of retraction at 31.47%, ahead of fraud and every other category. When a manuscript makes it through review and is later retracted for a preventable statistical reason, the cost falls on the publisher: the editorial overhead, the indexing scrutiny, and the author relationship that does not return.
MARS Global proposes an embedded biostatistics review service, placed inside the publisher's author journey at the point of submission and revision. Authors are referred at the moment statistical support is most needed. Every transaction is tied to a unique Manuscript ID before payment is taken. The publisher receives a secure, view-only dashboard and a monthly commission on net collected revenue. The service is narrow by design: statistical methods, results interpretation, tables and figures, sample size guidance, reviewer response support, and statistical language clarity.
MARS Global is not a manuscript-editing company adding statistics as a secondary line. Biostatistics and evidence generation are the core of the practice. The team holds an 89% Q1-journal publication success rate across partner manuscripts, has produced over 160 peer-reviewed publications, and has secured $4M in competitive research grants. The practice holds an active collaboration agreement with Research Square Company, announced through the UKSG newsletter in May 2022, with services delivered via Research Square's AJE division. The results of that programme, covering 7,144 clinical researchers across the Middle East and North Africa, were published as abstract OS18 in BMC Proceedings 2025, 19(9). This is an extension of operating relationships, not a standing start.
The publisher's problem
Statistical failure is your most costly editorial risk.
Three independent data points, each from a different research tradition, converge on the same finding.
The research on statistical error rates goes back to 1991, when Altman and Bland first quantified the problem. Thirty-three years of journal guidelines, reporting checklists, and statistical-editor programmes have not resolved it. The error rate in the literature is not a temporary trend. It is a structural condition of how manuscripts are prepared, and it has never been corrected at the submission stage where it originates.
Current AI statistical tools reach 92.5% accuracy on basic inferential tasks under expert prompting but fall to 32.5% without it, and independent testing in 2026 documents frequent hallucinations on complex multi-table datasets. Human expert review remains the only dependable intervention at this stage.
Between 21% and 62% of retractions are attributed to unintentional error rather than deliberate misconduct. These are the mistakes a pre-submission statistical review would catch, before the manuscript reaches the editorial desk.
What MARS Global delivers
Biostatistics only. Publication-stage. No scope creep.
Authors working on clinical and biomedical manuscripts receive expert review of exactly the statistical elements that cause peer-review rejection and post-publication retraction.
Assessment of the analytical approach against journal and reporting standards, including CONSORT, STROBE, PRISMA, and EQUATOR guidelines where applicable.
Clarification of findings before submission, including effect size reporting, confidence intervals, and the framing of statistical significance relative to clinical significance.
Accuracy review of all data-containing tables and figures, including axis labelling, units, decimal precision, and consistency between text and tabulated results.
Calculation verification and plain-language justification suitable for the methods section, addressing one of the most frequent points of statistical critique from reviewers.
Drafting of point-by-point statistical responses to peer-review critiques at revision stage, when statistical pressure on authors is highest.
Correction of imprecise or non-standard statistical terminology throughout the manuscript, producing the precise, consistent language that Q1-journal statistical editors expect.
Service tiers and author pricing
Three tiers. Transparent pricing.
All pricing aligns with publicly listed institutional biostatistics rates, which range from $89 to $300 per hour. The tiers are self-selecting by manuscript complexity.
Pre-submission review of statistical methods, results, and basic reporting accuracy. Most appropriate for authors preparing a first submission with a specific statistical question.
- Statistical methods review
- Results reporting check
- Tables and figures review
- Written correction summary
- Turnaround: 5 to 7 business days
Full review of statistical methodology, tables, figures, interpretation, and reporting language. Most appropriate at revision stage following statistical peer-review critique.
- Full statistical methodology review
- Reviewer response support
- Sample size and power assessment
- Statistical language rewrite
- Figure and table reconstruction
- Turnaround: 7 to 10 business days
Complex statistical revision including survival analysis, mixed models, meta-analysis methodology, and regulatory-level reporting standards. Includes direct biostatistician consultation.
- Complex modelling review
- Meta-analysis and systematic review stats
- Advanced reviewer response drafting
- R and SAS output interpretation
- Direct biostatistician consultation
- Turnaround: 10 to 14 business days
All pricing is aligned with public institutional and commercial biostatistics fee benchmarks. The publisher is not involved in setting author-facing pricing and has no liability for service delivery. MARS Global charges the author directly and remits commission monthly on net collected revenue only.
How the partnership works
Simple to integrate. Fully auditable from day one.
The workflow is designed to require minimal technical integration from the publisher and to produce a clean, reconcilable transaction record from the first referral.
A dedicated link or embedded widget appears to authors at submission, revision request, or resubmission. The placement is at the publisher's discretion. No technical build is required beyond a link placement or an API call if the publisher prefers a more integrated flow.
Authors enter their Journal Name and Manuscript ID before checkout is completed. This step is mandatory. Every transaction is tied to a specific submission record at the point of purchase, not retrospectively.
MARS Global's PhD biostatisticians complete the review within the agreed turnaround window. Manuscript content is handled under strict confidentiality protocols. No manuscript content is exposed in the partner dashboard at any stage.
Publishers receive secure, view-only dashboard access updated in real time, showing referral date, journal name, Manuscript ID, tier purchased, payment status, refund status, and commission accrued. Commission is paid on net received revenue only.
MARS Global credentials
Not a vendor claiming expertise. A record of published work.
Every credential below is sourced from published outputs, peer-reviewed journals, and publicly announced grants.
Partners and clients with published work
Selected grants confirming methodological credibility
Existing partnership
A collaboration agreement with Research Square Company.
This is an extension of existing publishing relationships, not a request to take a risk on an untested partner.
Research Square Company and American Journal Experts (AJE)
Research Square Company and MARS signed a collaboration agreement, announced through the UKSG newsletter on 18 May 2022, to support clinical and regulatory scientists across the Middle East and North Africa. Through the agreement, Research Square Company supports MARS training and consulting efforts via its AJE division, providing MARS trainees with discounted English editing, translation, manuscript formatting, webinars, and conferences. The results of this partnership were delivered through a structured webinar series for 7,144 healthcare professionals and published as abstract OS18 in BMC Proceedings 2025, 19(9), with Nouran Hamza and Sara Adel of MARS Global as corresponding authors.
Commercial model
Revenue share. Clean accounting.
Commission on cash received only.
The preferred commercial structure is a referral-based revenue share. MARS Global charges the author for the service and remits a monthly commission to the publisher on net collected revenue. The standard commission range is 15% to 20%, confirmed at the point of signing.
Refunds, chargebacks, and unpaid invoices are excluded from commission calculations until cash is actually received. There is no minimum volume commitment and no upfront fee to the publisher.
The publisher does not pay for the service, does not take on liability for service delivery, and does not handle any author payment. The commercial model is designed so that the publisher's finance team can reconcile every line of income against its own editorial records using Manuscript IDs.
What the publisher receives
Proposed partnership terms
Simple to implement. Built for publisher finance and audit.
Next steps
Your authors have a statistical problem. We have solved it 160 times in print.
A 20-minute conversation is enough to establish whether this partnership fits your author journey. We can begin with a named-journal pilot at no risk to the publisher.
contact
Address: Office 183dv Unit 5, 399-405 Oxford Street, Mayfair, London, United Kingdom, W1C 2BU, Company number 17042542
Email: info@mars-global.co.uk
Phone: +44 7737 450171
Address2: 63 Syria St. Giza, Egypt
Email: info@marsresearchhub.com
Copyright 2026 Medical Agency for Research and Statistics , UK - Privacy Policy
Copyright 2.026 Medical Agency for Research and statistics, MENA